Applied BioSciences Enters into $1 Million Equity Financing Agreement with Triton Funds

LOS ANGELES, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Applied BioSciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it has entered into a Common Stock Purchase Agreement with Triton Funds, LP, a Delaware limited partnership (“Triton Funds”), in which Triton Funds has agreed to purchase up to $1,000,000 of registered common stock of the Company in connection with a separate Registration Rights Agreement.

“We are excited to be working with a cutting-edge organization focused on financing emerging growth companies. Our agreement with Triton Funds is highly advantageous to the company in that it provides growth funding to accelerate our rapid growth in the consumer and pet CBD market, while affording Triton Fund a significant long-term upside opportunity through their equity investment. It's beneficial for everyone, especially our shareholders who will benefit by the significant investment Triton Funds is making in our company,” stated Chris Bridges, President.

“Applied BioSciences is a company that has a very strong reach in its field. With a management team like Chris Bridges and JJ Southard we are confident they can capitalize on their visions and goals,” said Yash Thukral, Founder at Triton Funds LLC. “We are excited to be working with a company who challenges the limits of its industry.”

“At Triton Funds we dive in and invest in companies that make a positive impact in evolving spaces, such as the CBD industry. Applied BioSciences does exactly that by diversifying themselves amongst different CBD and hemp products, ranging from creams and oils to capsulses and vapes. Moreover, with a strong management team and great financials, we expect to grow and evolve with Applied BioSciences,” said Ashkan Mapar.

Applied BioSciences products are USDA NOP certified organic, non-GMO, vegan, paleo, gluten-free, sugar-free and THC-free. The products are formulated with organic 99%+ pure cannabidiol along with our proprietary blend of certified organic botanicals, herbals and essential oils to further optimize bioavailability.

About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

About Triton Funds 

Triton Funds, La Jolla, California, was started by three undergraduate students from Southern California aspiring to create an investment fund with a 'millennial touch'. It began on the streets of La Jolla in search of investors willing to back our idea of a student-run fund that creates a greater sense of community through investments in local companies and entrepreneurs, philanthropy, and guidance to fellow college students interested in the finance field. As a result, local limited partners, coupled with the support of our advisory board, established Triton Funds, creating real-world opportunities for college students to guide its investments in growing companies. For more information, visit, https://www.tritonfunds.com.

Contact
Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com
Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com

Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet

Safe Harbor Statement

Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.   Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Applied Biosciences Corp. (the “Company”) or its management, identify forward-looking statements.  These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.  Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

• 1